NanoString Technologies Inc. Announces Positive Results From Second Validation Study of PAM50-based Breast Cancer Assay

Published: Dec 06, 2012

SEATTLE & SAN ANTONIO--(BUSINESS WIRE)--NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostic products, today announced positive results from the second clinical validation study of its in vitro diagnostic breast cancer assay based on the PAM50 gene expression signature. The study, which evaluated samples from more than 1,400 patients enrolled in the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG8) trial, met its primary and secondary objectives and demonstrated the ability of the PAM50 test to indicate the risk of distant recurrence in postmenopausal women with hormone receptor-positive (HR+) early-stage breast cancer treated with endocrine therapy alone. Results were presented by the study’s investigators during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.

Back to news